|Articles|August 12, 2014

Special Reports

  • Gastrointestinal Cancers (Issue 2)
  • Volume 2
  • Issue 1

Predicting Outcomes With First-Line Antiangiogenics Plus Chemotherapy in mCRC

Paulo Marcelo Hoff, MD, PhD, FACP, University of São Paulo, Brazil, discusses predicting outcomes with first-line antiangiogenics plus chemotherapy in metastatic colorectal cancer (mCRC).

Paulo Marcelo Hoff, MD, PhD, FACP, University of São Paulo, Brazil, discusses predicting outcomes with first-line antiangiogenics plus chemotherapy in metastatic colorectal cancer (mCRC).

Learn about adverse events associated with regorafenib for mCRC > >


Latest CME